Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma

Leuk Res. 2013 Sep;37(9):1120-4. doi: 10.1016/j.leukres.2013.05.003. Epub 2013 Jun 12.

Abstract

Impaired function of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway genes leads to immunodeficiency and various hematopoietic disorders. We evaluated the association between genetic polymorphisms (SNPs) in 12 JAK/STAT pathway genes (JAK3, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6, SCOS1, SCOS2, SCOS3, and SCOS4) and NHL risk in a population-based case-control study of Connecticut women. We identified three SNPs in STAT3 (rs12949918 and rs6503695) and STAT4 (rs932169) associated with NHL risk after adjustment for multiple comparison. Our results suggest that genetic variation in JAK/STAT pathway genes may play a role in lymphomagenesis and warrants further investigation.

Keywords: Case–control study; JAK/STAT signaling pathway; Non-Hodgkin lymphoma; Polymorphism.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Aged
  • Biomarkers, Tumor / genetics*
  • Case-Control Studies
  • Female
  • Humans
  • Janus Kinase 1 / genetics*
  • Lymphoma, Non-Hodgkin / genetics*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • STAT Transcription Factors / genetics*
  • Suppressor of Cytokine Signaling 1 Protein
  • Suppressor of Cytokine Signaling Proteins / genetics*

Substances

  • Biomarkers, Tumor
  • SOCS1 protein, human
  • STAT Transcription Factors
  • Suppressor of Cytokine Signaling 1 Protein
  • Suppressor of Cytokine Signaling Proteins
  • JAK1 protein, human
  • Janus Kinase 1